Enterprise Value
13.61M
Cash
6.779M
Avg Qtr Burn
-6.926M
Short % of Float
2.89%
Insider Ownership
3.96%
Institutional Own.
57.74%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
MT-8421 Details Cancer, Solid tumor/s | Phase 1 Data readout | |
MT-6402 Details Solid tumor/s, Cancer | Phase 1 Data readout | |
MT-3724 with GEMOX (CD20) Details DLBCL (Diffuse large B-cell lymphoma) | Failed Discontinued | |
MT-3724 (CD20) with Lenalidomide Details DLBCL (Diffuse large B-cell lymphoma) | Failed Discontinued | |
MT-3724 (CD20) monotherapy Details DLBCL (Diffuse large B-cell lymphoma) | Failed Discontinued | |
MT-5111 Details Breast cancer, Cancer | Failed Discontinued | |
MT-0169 (TAK-169) (CD38) Details Multiple myeloma, Extramedullary myeloma | Failed Discontinued |